This announcement is a separate document:
北京市天元律师事务所关于昭衍新药2023年年度股东大会、2024年第二次A股类别股东会议及2024年第二次H股类别股东会议的法律意见
Legal opinion of Tianyuan Law Firm on the 2023 annual shareholders' meeting, 2024 second A-share category shareholder meeting and 2024 second listed in Hong Kong category shareholder meeting of Joinn Laboratories.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.